Is Daclatasvir valid?
Daclatasvir has a corresponding effect on hepatitis C genotype, liver injury and previous treatment history. Patients with cirrhosis have no response to patients with mild or moderate hepatic fibrosis. Daclatasvir is not a single drug treatment, is the need for combined treatment of hepatitis C.
However, there are no significant differences in the number of factors that have traditionally been predicted for interferon-based adverse effects in interferon therapy. These factors can be overcome by prolonging treatment or adding another direct effect of antiviral drugs or ribavirin.
Daclatasvir treatment response
Patients with sustained virological response (SVR) were still unable to detect HCV viral load (known as "SVR12") at 12 weeks after completion of treatment and were considered to be cured.
The second phase of the study (AI444040) studied HCV genotype 1, previously untreated patients and had been treated with pegylated interferon and ribavirin with older HCV protease inhibitors, the Victrelis, Or patients treated with Increvo (Incivo).
The cure rate of the two groups of patients treated with Daclatasvir plus 12 months or 24 weeks was 100%. Daclatasvir was also tested for 24 weeks in a small number of previously untreated HCV genotype 2 or 3 patients. Daclatasvir was administered alone with 96% genotype 2 and 89% genotype 3 patients. The addition of ribavirin to cure genotype 3 was as high as 100%.
In the COMMAND-4 trial (AI444042), Daclatasvir was used in combination with pegylated interferon and ribavirin for previously untreated HCV genotype 4 patients. Approximately 80% of patients with or without cirrhosis were cured with a triple combination - more than twice the triple combination of interferon and ribavirin alone. The effectiveness of Daclatasvir in "real world" use may be slightly lower than the cure rate seen in clinical trials, in part because the patient may be more severe or have other conditions that make treatment more complex.